Form 4: Moderna Chief Legal Officer Reports Future Stock Transactions

Moderna's Chief Legal Officer, Shannon Thyme Klinger, filed a Form 4 detailing future acquisitions and dispositions of common stock related to RSU vesting.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported transactions involving the company's common stock.
• On August 27, 2025, Klinger acquired 774 shares of common stock through the conversion of restricted stock units (RSUs).
• On the same date, 375 shares were disposed of at a price of $24.73 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions on August 27, 2025, Klinger beneficially owned 27,882 shares of common stock directly.
• On August 28, 2025, Klinger acquired an additional 329 shares of common stock from RSU conversion.
• Concurrently, 160 shares were disposed of at $25.10 per share to cover tax withholding obligations for the RSU vesting.
• After the August 28, 2025 transactions, Klinger's direct beneficial ownership of common stock was 28,051 shares.
• The restricted stock units convert into common stock on a one-for-one basis.
• One RSU award had 25% of shares vest on February 27, 2025, with the remainder vesting in twelve equal quarterly installments.
• Another RSU award had 25% of shares vest on February 28, 2024, with the remainder vesting in twelve equal quarterly installments.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and tax-related sales), which are neutral in sentiment as they represent scheduled compensation events rather than discretionary trading.

Positives

• The acquisition of shares through RSU conversion indicates continued compensation and alignment of executive interests with shareholder value.
• The vesting of restricted stock units represents a scheduled compensation event for the Chief Legal Officer.

Negatives

• A portion of shares were disposed of to cover tax withholding obligations, reducing the direct beneficial ownership of the reporting person.

Future Outlook

The filing details pre-scheduled or future-dated transactions related to RSU vesting, indicating ongoing executive compensation structure.

Industry Context

This filing is a routine disclosure of insider stock transactions, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape for the biotechnology sector.

Comparison to Industry Standards

• The reported transactions, involving RSU vesting and subsequent tax-related dispositions, are standard practices for executive compensation in publicly traded companies, including those in the biotechnology industry like Pfizer or BioNTech.
• The volume of shares involved is typical for an executive at this level, reflecting a portion of their equity compensation rather than a significant market-moving event.

Stakeholder Impact

• Shareholders: Minor impact as these are routine compensation-related transactions and do not signal a significant change in insider sentiment or company fundamentals.
• Employees: Reflects standard executive compensation practices, which can be a benchmark for other employees with equity awards.

Key Dates

Keywords

Moderna, MRNA, Shannon Thyme Klinger, Chief Legal Officer, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Transactions, Tax Withholding, Beneficial Ownership